Iovance Biotherapeutics Inc

Common Name

Iovance Biotherapeutics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

838

Ticker

IOVA

Exchange

NASDAQ/NMS

Website

www.iovance.com

Description

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology cen... Show more

Financial Statements of Iovance Biotherapeutics

Below are the financial statements of Iovance Biotherapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in thousands of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	115,694^a	114,888^a
Trade accounts receivable	69,340^a	151^a
Short-term investments	208,087^a	164,979^a
Inventory	51,520^a	10,372^a
Prepaid expenses and other assets	12,377^a	17,458^a
Total current assets	457,018^a	307,848^a
Assets	—	—
Property and equipment, net	109,081^a	114,030^a
Intangible assets, net	282,398^a	229,258^a
Operating lease right-of-use assets	55,201^a	62,515^a
Restricted cash	6,359^a	66,430^a
Long-term assets	369^a	270^a
Total assets	910,426^a	780,351^a
Current liabilities	—	—
Accounts payable	27,509^a	33,123^a
Accrued expenses and other liabilities	81,936^a	69,406^a
Operating lease liabilities	12,896^a	7,777^a
Total current liabilities	122,341^a	110,306^a
Non-current liabilities	—	—
Operating lease liabilities - non-current	44,365^a	67,085^a
Deferred tax liabilities	32,315^a	17,347^a
Long-term note payable	1,000^a	1,000^a
Total non-current liabilities	77,680^a	85,432^a
Liabilities and stockholders’ equity	—	—
Total liabilities	200,021^a	195,738^a
Stockholders’ equity	—	—
Series A convertible preferred stock	0^a	0^a
Series B convertible preferred stock	3^a	3^a
Common stock	13^a	11^a
Accumulated other comprehensive loss (income)	-1,046^a	2,526^a
Additional paid-in capital	3,095,987^a	2,594,448^a
Accumulated deficit	-2,384,552^a	-2,012,375^a
Total stockholders’ equity	710,405^a	584,613^a
Total liabilities and stockholders’ equity	910,426^a	780,351^a

Verified Sources Behind Iovance Biotherapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Iovance Biotherapeutics’s data sources below and access millions more through our Disclosure Search.

a. Iovance Biotherapeutics's Annual Report 2024

Trace every data point back to Iovance Biotherapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Iovance Biotherapeutics Inc

Financial Statements of Iovance Biotherapeutics

Verified Sources Behind Iovance Biotherapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

Vericel Corp

Blueprint Medicines Corp

ADMA Biologics Inc

Ultragenyx Pharmaceutical Inc

Axsome Therapeutics Inc